Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      More about Acyclovir Neurotoxicity in Patients on Haemodialysis

      , , ,

      Nephron

      S. Karger AG

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Acyclovir is an efficient treatment in virus infections of the herpes family. Now that it has been in use for more than 10 years, neurotoxicity is a well-known complication, especially after the intravenous use [1]. However, recently cases of neurotoxicity after the oral use in patients with terminal renal failure (TRF) on haemodialysis (HD) have been described [2–5]. This has been associated with high serum levels of the drug, representing an overdose and a significant modification of the dosage has been recommended in these patients [2, 4, 5]. HD has been shown to be an efficient method of elimination as well as a diagnostic method to differentiate between acyclovir neurotoxicity and encephalitic herpes [6].

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1998
          February 1998
          26 January 1998
          : 78
          : 2
          : 228-229
          Affiliations
          Servicio de Nefrología, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain
          Article
          44919 Nephron 1998;78:228–229
          10.1159/000044919
          9496746
          © 1998 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Tables: 1, References: 8, Pages: 2
          Product
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/44919
          Categories
          Letter to the Editor

          Cardiovascular Medicine, Nephrology

          Comments

          Comment on this article